Loading
AI is starting to decide which patients get which cancer drug. Every change to the software should be tested against a fixed public set of cases before it is used on patients.
AI-based scoring of HER2, PD-L1 and other markers is entering clinical use. Software updates can shift positivity rates silently. Regulators (FDA's predetermined change control plans, EU AI Act) are building frameworks. A concrete requirement for oncology companion diagnostic algorithms: every version must report performance on a locked public reference set, changes must be logged with effect on positivity rates, and laboratories must record the algorithm version in each patient report.
Shares Public gold-standard datasets for validating every cancer biomarker test, PathAI, Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Paige AI.
Shares PathAI, Paige AI, AI quantification of HER2-low and HER2-ultralow, AI that is built but not validated or deployed.
Shares PathAI, Paige AI, Pathology & radiology foundation models, AI that is built but not validated or deployed.
Shares PathAI, Paige AI, AI quantification of HER2-low and HER2-ultralow, Pathology & radiology foundation models.
Shares PathAI, Paige AI, Pathology & radiology foundation models, AI that is built but not validated or deployed.
Shares Public gold-standard datasets for validating every cancer biomarker test, Pathology & radiology foundation models, AI that is built but not validated or deployed, Digital pathology & AI.
Shares Paige AI, Pathology & radiology foundation models, Digital pathology & AI.